Skip to main contentAI and Advanced
/
NOVARTIND · NSEBSE SENSEX74,515.94+0.24%BSE |
NIFTY 5023,312.7+0.41%NSE |
NIFTY BANK56,265.35-0.05%NSE |
NIFTY IT29,067.2-0.07%NSE |
NIFTY AUTO27,227.75+1.24%NSE |
NIFTY FMCG45,698.5+0.31%NSE |
NIFTY PHARMA26,483.55+1.29%NSE |
NIFTY 50022,675.3+0.64%NSE |
NO
NSE · Equity shares · Biotechnology & Drugs145.50 · 7.29%
Novartis India NOVARTIND
NSE:INR 2,141
BSE:INR 2,141
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for NOVARTIND
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,995.5
Day rangeINR 1,980 — INR 2,178.1
52-week rangeINR 750 — INR 2,588.8
Volume1.22 L
Market cap3,948.06
P/E36.21
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)354.33
Net Income (INR Cr)93.18
Rev Growth (5 Year %)-1.46
EPS Growth (5 Year %)34.85
P/E Ratio36.21
EPS37.74
Research path: Interpret Novartis India's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
NOVARTINDNovartis India1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 978.27 | 947.81 | 924.93 |
| Cash Equivalents | 667.7 | 49 | 40 |
| Other Liabilities Total | 13.9 | 17.59 | 17.84 |
| Common Stock Total | 12.34 | 12.34 | 12.34 |
| Other Current Assets Total | 9.53 | 2.66 | 2.14 |
| Total Assets | 978.27 | 947.81 | 924.93 |
| Current Portof LT Debt/Capital Leases | 1.64 | 1.85 | 1.88 |
| Total Equity | 817.83 | 784.96 | 744.82 |
| Long Term Investments | 1.06 | 0.16 | 0.26 |
| Retained Earnings(Accumulated Deficit) | 805.49 | 772.62 | 732.48 |
| Total Common Shares Outstanding | 2.47 | 2.47 | 2.47 |
| Tangible Book Valueper Share Common Eq | 331.23 | 317.92 | 301.66 |
| Total Liabilities | 160.44 | 162.85 | 180.11 |
| Total Debt | 3.21 | 5.06 | 6.97 |
| Short Term Investments | 0.65 | 585 | 540 |
| Cashand Short Term Investments | 668.35 | 637.07 | 584.98 |
| Total Receivables Net | 37.05 | 61.78 | 64.75 |
| Accounts Receivable-Trade Net | 37.05 | 49.04 | 50.79 |
| Property/Plant/Equipment Total-Net | 2.88 | 4.54 | 6.94 |
| Total Current Liabilities | 144.97 | 142.05 | 157.2 |
| Total Inventory | 53.32 | 41.84 | 45.5 |
| Accounts Payable | 54.65 | 51.47 | 61.59 |
| Other Currentliabilities Total | 88.68 | 46.73 | 45.36 |
| Total Long Term Debt | 1.57 | 3.21 | 5.07 |
| Other Long Term Assets Total | 87.24 | 134.41 | 148.34 |
| Note Receivable-Long Term | 118.84 | 62.88 | 70.13 |
| Total Current Assets | 768.25 | 745.82 | 699.26 |
| Capital Lease Obligations | 1.57 | 3.21 | 5.07 |
| Accumulated Depreciation Total | Not available | -2.82 | -6.92 |
| Accrued Expenses | Not available | 42 | 48.35 |
| Prepaid Expenses | Not available | 2.47 | 1.89 |
| Cash | Not available | 3.07 | 4.98 |
| Property/Plant/Equipment Total-Gross | Not available | 7.36 | 13.86 |
| Notes Payable/Short Term Debt | Not available | 0 | 0.02 |
| ESOP Debt Guarantee | Not available | Not available | 0 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %-44.77
Margins
Operating Margin 12m26.97
Operating Margin 5y Avg14.97
Net Profit Margin 12m26.38
Net Profit Margin 5y20.77
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio11.14
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk51.23
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 70.68%
- FII
- 0.16%
- MF
- 0.69%
- Other
- 28.47%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Novartis India Ltd Hits Intraday Low Amid Price Pressure on 3 June 2026 - Markets MojoMarket news · 3 Jun 2026, 10:38 am
Novartis India Ltd Hits Intraday Low Amid Price Pressure on 3 June 2026 Markets Mojo
Novartis India Ltd is Rated Hold - Markets MojoMarket news · 3 Jun 2026, 10:11 am
Novartis India Ltd is Rated Hold Markets Mojo
Broad-Based Technical Strength Lifts Novartis India Ltd to 52-Week High of Rs 1462.5 - Markets MojoMarket news · 27 May 2026, 10:57 am
Broad-Based Technical Strength Lifts Novartis India Ltd to 52-Week High of Rs 1462.5 Markets Mojo
Strong Momentum Meets Stretched Valuations as Novartis India Ltd Reaches All-Time High - Markets MojoMarket news · 27 May 2026, 10:41 am
Strong Momentum Meets Stretched Valuations as Novartis India Ltd Reaches All-Time High Markets Mojo
Strong Momentum Meets Stretched Valuations as Novartis India Ltd Reaches All-Time High - Markets MojoMarket news · 26 May 2026, 1:31 pm
Strong Momentum Meets Stretched Valuations as Novartis India Ltd Reaches All-Time High Markets Mojo
Novartis India Appoints Gowree Gokhale as Independent Director - scanx.tradeMarket news · 19 May 2026, 12:30 pm
Novartis India Appoints Gowree Gokhale as Independent Director scanx.trade
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.25.0000 per share(500%)Final Dividend
- annual General MeetingPOM
Rusaka Markets Community
Discussion and sentiment for Novartis India
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Novartis India Limited is an India-based pure-play medicines company. The Company is focused on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience and oncology. In addition to two established technology platforms (chemistry and biotherapeutics), three emerging platforms (gene & cell therapy, radioligand therapy and xRNA) are added for continued investment into R&D and manufacturing scale. The Company’s brands hold key positions in therapeutic areas, such as, Voveran, which is the brand for bone and pain; Simulect, Certican, Sandimmun, Neoral, and Myfortic, which is the brand for transplantation immunology; and Tegrital and Exelon, which is the brand for neurosciences. Its pipeline includes AAA614 Solid tumors, AAA617 Pluvicto Oligometastatic prostate cancer, Pluvicto Metastatic hormone sensitive prostate cancer (mHSPC), 225Ac-PSMA-617 Metastatic castration-resistant prostate cancer (mCRPC), and others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- NOVARTIND
- BSE Code
- 500672
Questions
Stock FAQ
What is the symbol and ISIN of Novartis India?
Novartis India has the symbol NOVARTIND and ISIN - INE234A01025.
What is the current price of Novartis India?
Novartis India is currently trading at INR 2,141.00.
What are the year high and year low of Novartis India?
Novartis India has a year high of INR 2,588.80 and a year low of INR 750.00.
What is the market capitalization of Novartis India?
Novartis India has a market capitalization of INR 3,948.06 crore.
What is the P/E ratio of Novartis India?
Novartis India has a P/E ratio of 36.21.
What is the dividend yield of Novartis India?
Novartis India has a dividend yield of 0.00%.
How is the financial performance of Novartis India based on revenue, net income, and EPS?
Novartis India has revenue of INR 354.33 crore, net income of INR 93.18 crore, and EPS of INR 39.61.
What is the book value of Novartis India?
Novartis India has a book value of NA.
What is the debt-to-equity ratio of Novartis India?
Novartis India has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Novartis India?
Novartis India has a price-to-book ratio of NA and a price-to-sales ratio of 11.14.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.